NUFORMIX PLC LS -001
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis… Read more
NUFORMIX PLC LS -001 (1RT) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, NUFORMIX PLC LS -001 (1RT) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
NUFORMIX PLC LS -001 - Net Assets Trend (None–None)
This chart illustrates how NUFORMIX PLC LS -001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NUFORMIX PLC LS -001 (None–None)
The table below shows the annual net assets of NUFORMIX PLC LS -001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to NUFORMIX PLC LS -001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
NUFORMIX PLC LS -001 Competitors by Market Cap
The table below lists competitors of NUFORMIX PLC LS -001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rightscorp Inc
PINK:RIHT
|
$1.94 Million |
|
VIMAB Group AB
ST:VIMAB
|
$1.94 Million |
|
Kings Entertainment Group Inc.
PINK:KENGF
|
$1.94 Million |
|
TechnoDex Bhd
KLSE:0132
|
$1.94 Million |
|
Crypto Co
PINK:CRCW
|
$1.94 Million |
|
ASHDOD REFINERY LTD
TA:ARF
|
$1.94 Million |
|
Netcapital Inc
NASDAQ:NCPL
|
$1.94 Million |
|
SpringBig Holdings Inc.
NASDAQ:SBIG
|
$1.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NUFORMIX PLC LS -001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares NUFORMIX PLC LS -001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently NUFORMIX PLC LS -001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares NUFORMIX PLC LS -001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NUFORMIX PLC LS -001 (1RT) | €- | N/A | N/A | $1.94 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |